Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-CD33A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Induction with SGN-CD33A | EXPERIMENTAL | 7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A |
| Consolidation with SGN-CD33A | EXPERIMENTAL | High dose cytarabine for consolidation + SGN-CD33A (28-day cycles) |
| SGN-CD33A Maintenance | EXPERIMENTAL | SGN-CD33A Monotherapy (42-day cycles) |
| Induction and Consolidation with SGN-CD33A | EXPERIMENTAL | 7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A |
| Name | Type | Description |
|---|---|---|
| Standard dose cytarabine for induction | DRUG | 100 mg/m2/day Days 1-7 |
| SGN-CD33A | DRUG | Given intravenously Day 1 or Days 1 and 4 of each cycle |
| Daunorubicin | DRUG | 60 mg/m2/day Days 1-3 |
| High dose cytarabine for consolidation | DRUG | 3g/m2 on Days 1, 3, and 5 of each cycle |
Inclusion Criteria: * All subtypes of Acute Myeloid leukemia (except for acute promyelocytic leukemia) * Eastern Cooperative Oncology Group status of 0 or 1 * Adequate baseline renal and hepatic function * Central venous access * Part specific requirements: eligible to receive induction; achieved C...
SGN-CD33A is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia (AML), also known as Acute Myelogenous Leukemia. It is currently in Phase 1 clinical development and has not been approved by the FDA.
SGN-CD33A is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Acute Myeloid Leukemia.
SGN-CD33A is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its safety and potential efficacy in patients with Acute Myeloid Leukemia.
SGN-CD33A has been studied in one clinical trial, identified as NCT02326584, titled "A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML." This Phase 1 trial enrolled 116 participants in the United States and has been completed.
SGN-CD33A is also known as vadastuximab talirine. The drug is being developed by Pfizer for the treatment of Acute Myeloid Leukemia. It is an investigational agent that has been evaluated in a Phase 1 clinical trial.